

6 September 2021

ASX ANNOUNCEMENT

Commonwealth Government funds clinical trials for JAT's Platinum immunity support formulas tested by The University of Sydney against SARS-CoV-2

Jatcorp Limited (ASX: JAT) is pleased to announce that it has received significant Commonwealth financial assistance in the next step of the commercialisation of the two formulas (**Jinvigorate Platinum and Moroka Platinum**) developed by JAT that demonstrated in a research project undertaken with The University of Sydney they neutralised SARS-CoV-2 infection in certain circumstances. The assistance is being provided by the Australian Government Department of Industry, Science, Energy and Resources as part of the Entrepreneurs' Programme.

Background

On 17 May 2021, JAT announced the results of The University of Sydney research project, where the final report stated:

- *Five supplementary food formulas developed by Jatcorp were tested against SARS-CoV-2 in vitro.*
- *All Jatcorp supplementary food formulas demonstrated promising antiviral activity against the SARS-CoV-2 virus in this in vitro assay.*
- *All five formulas neutralised SARS-CoV-2 infection at concentrations of 0.4-1.0 mg/ml in this model.*
- *We employed a sophisticated in vitro biological assay to model inhibition of COVID-19 infection on a cellular level. This system utilises human cells rather than non-human/primate cells and is currently used to assay human clinical samples for SARS-CoV-2 infection.*
- *Continued research can be undertaken to further test new and other formulation of Jatcorp products for their potent antiviral activities by the in vitro model.*

Market Development

JAT has currently invested in excess of \$500,000 to develop the immunity support formulas, including Jinvigorate Platinum and Moroka Platinum, which were the subject of The University of Sydney research project referred to above.

The next step in the market development of the immunity support formulas is the clinical trial described below, for which the funding assistance is being provided by the Australian Government Department of Industry, Science, Energy and Resources as part of the Entrepreneurs' Programme.

About the Clinical Trial

In order to obtain scientific evidence of the effect of Jinvigorate Platinum and Moroka Platinum on humans, JAT has commissioned a research project to be undertaken by Royal Melbourne

Institute of Technology (RMIT). The research project will have duration of 6 -12 months and will cost approximately \$200,000. The cost includes payments to RMIT and the supply of products by JAT to be used in the research project.

JAT has two grants from the Australian Government Department of Industry, Science, Energy and Resources Innovation Connections to assist in funding the cost of the research project. Details of the grants, which amount to slightly less than 50% of the cost of the research project, can be viewed at <https://www.grants.gov.au/>

The RMIT research project is titled:

Immune enhancing efficacy of LF-Ig formula in healthy human subjects

The objective of the research project is to undertake a clinical trial to investigate the ability of Jinvigorate Platinum and Moroka Platinum to promote improved immune function in healthy adults.

The hypothesis of the research project to be investigated by RMIT is that the healthy human adults subject of the research project will, on consuming JAT's LF-Ig formulas (Jinvigorate Platinum and Moroka Platinum), exhibit improved immune function and responses to a model vaccine, and may be better protected against upper respiratory tract infections (such as Flu and Covid).

The human subjects will be aged between 20 and 70 years of age and a total of 75 subjects will be screened/recruited.

This reinforces JAT's exceptional and unrivalled commitment towards providing its patrons with innovative and premium supplementary health food products. Jinvigorate Platinum and Moroka Platinum are aligned with our strategy and core values which is to empower people so that they can live brilliantly.

This announcement is authorised by JAT's Managing Director, Wilton Yao.

Wilton Yao
Managing Director
Ph: +61 3 9090 759

About Jatcorp Limited

Jatcorp (ASX: JAT), at the forefront of innovative technology servicing the world's largest retail markets. With a track record of successful product development and distinguished technology. JAT is a leading producer of supplementary food products, plant-based meat and Dairy food products.